PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. ("Guardant Health†) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its upsized offering of $350.0 million aggregate principal amount of 0% convertible senior notes due 2033 (the "notes†) in a private offering (the "convertible notes offering†) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act†). Th. ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. ("Guardant Health†) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of an upsized underwritten public offering of 3,333,333 shares of Guardant Health's common stock at a public offering price of $90.00 per share (the "common stock offering†). The size of the common stock offering was increased from the previously announced $250.0 million of shares of common stock. In addition, Guardant Health granted the u. ...

Guardant Health Announces Proposed Public Offering of Common Stock Share PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. ("Guardant Health†) (Nasdaq: GH), a leading precision oncology company, today announced the commencement of an underwritten public offering of $250.0 million of shares of Guardant Health's common stock (the "common stock offering†). Guardant Health also intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common sto ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. ("Guardant Health†) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $300.0 million aggregate principal amount of convertible senior notes due 2033 (the "notes†) in a private offering (the "convertible notes offering†) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act†). Guardant Health also. ...

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?Read Next:Loading...Loading... ...

Guardant Health, Inc. ( GH ) is a cancer genomics diagnostics company. GH leverages the SMART platform, which spans screening, therapy selection, minimal residual disease (MRD), and surveillance across all stages of cancer. GH’s business segments include Oncology as the anchor, Screening, and Biopharma & Data. InMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science f ...

We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Guardant Health Inc. (NASDAQ:GH) is one of the best-performing stocks on Thursday. Guardant Health soared to a fresh record high on Thursday, as investors took heart from an impressive earnings performance and a higher growth outlook for the full-year period. During the trading session, Guardant Health Inc. (NASDAQ:GH) jumped to its highest level of $95.88 before paring gains to end the day just up by 27.87 percent at $92.41 apiec ...

Key Points The cancer-focused biotech surprised on the upside for both revenue and profitability in its latest reported quarter. Revenue rose by almost 40% year over year in that period. 10 stocks we like better than Guardant Health › Guardant Health (NASDAQ: GH) unveiled its latest set of quarterly results on Thursday, and the biotech's encouraging performance gave the stock significant upward momentum. The company's shares were up by 28% week to date as of early Friday morning, according to data c ...

Richard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved by identifying businesses with secular growth opportunities in markets with barriers to entry. Narweena’s research process is focused on company and industry fundamentals with the goal of uncovering unique insights. Narweena has a high risk appetite and a long-term ...

Richard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved by identifying businesses with secular growth opportunities in markets with barriers to entry. Narweena’s research process is focused on company and industry fundamentals with the goal of uncovering unique insights. Narweena has a high risk appetite and a long-term ...